Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,460.00    44.00 (3.11%)
Bid:
1,453.00
Ask:
1,454.00
Spread: 1.00 (0.069%)
Market Cap: £3.10b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

10 Jan 2011 11:51

RNS Number : 1766Z
Hikma Pharmaceuticals Plc
10 January 2011
Β 

ο»Ώ

Annex DTR3

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

All relevant boxes should be completed in block capital letters

1.

Name of the Issuer:

Β 

Hikma Pharmaceuticals PLC

2.

State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance with LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Companies Act (2006):

DTR 3.1.2 R

3.

Name of person discharging managerial responsibilities/director:

Samih Darwazah, Said Darwazah, Mazen Darwazah and Ali Al-Husry

4.

State whether notification relates to a person connected with a person discharging managerial responsibilities/ director named in 3 and identify the connected person:

Yes: Darhold Limited

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest:

Beneficial interest Darhold Limited

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares:

Ordinary Shares

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them:

BNP Paribas Securities Services account for an on behalf of Credit Suisse AG

8.

State the nature of the transaction:

The transaction comprises the cancellation of a variable forward sale by Darhold of up to 1,125,000 Ordinary Shares.

In connection with such cancellation:

(a) 1,125,000 Ordinary Shares previously lent by Darhold will be returned; and

(b) 1,125,000 Ordinary Shares previously pledged by Darhold will be released from such pledge arrangements.

9.

Number of shares, debentures or financial instruments relating to shares acquired: N/A

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage): N/A

11.

Number of shares, debentures or financial instruments relating to shares disposed:

N/A

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage):

N/A

13.

Price per share or value of transaction:

N/A

Β 

14.

Date and place of transaction:

London, 9 January 2011

Β 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage):

57,183,028 (29.56%)

16.

Date issuer informed of transaction:

9 January 2011

Β 

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

17.

Date of grant

18.

Period during which or date on which exercisable

19.

Total amount paid (if any) for grant of the option

20.

Description of shares or debentures involved (class and number)

21.

Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

22.

Total number of shares or debentures over which options held following notification

23.

Any additional information

24.

Name of contact and telephone number for queries

Β 

Name of authorised official or issuer responsible for making notification

Henry Knowles, Company Secretary, Hikma Pharmaceuticals PLC

Date of notification 10 January 2011

Β 

Notes:

This form is intended for use by an issuer to make a RIS notification required by DTR 3.1.4

(1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2) An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3) An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
RDSBBGDBUSBBGBG
Date   Source Headline
2nd Jun 202612:42 pmRNSDirector/PDMR Shareholding
1st Jun 20264:16 pmRNSTotal Voting Rights
1st Jun 202612:11 pmRNSTransaction in Own Shares
27th May 202610:05 amRNSTransaction in Own Shares
26th May 202610:30 amRNSTransaction in Own Shares
18th May 202610:55 amRNSTransaction in Own Shares
15th May 20269:45 amRNSChange of Registered Office
11th May 20261:10 pmRNSTransaction in Own Shares
6th May 20263:08 pmRNSDirector/PDMR Shareholding
5th May 20269:55 amRNSTransaction in Own Shares
1st May 202610:36 amRNSTotal Voting Rights
28th Apr 20261:29 pmRNSDirector/PDMR Shareholding
27th Apr 202611:55 amRNSTransaction in Own Shares
23rd Apr 20263:42 pmRNSResult of AGM
23rd Apr 20267:00 amRNSTrading Statement
20th Apr 202610:55 amRNSTransaction in Own Shares
13th Apr 20263:29 pmRNSDirector/PDMR Shareholding
13th Apr 202611:10 amRNSTransaction in Own Shares
9th Apr 20264:43 pmRNSDirector/PDMR Shareholding
7th Apr 20269:42 amRNSTransaction in Own Shares
1st Apr 202611:11 amRNSTotal Voting Rights
30th Mar 202610:55 amRNSTransaction in Own Shares
23rd Mar 202611:00 amRNSTransaction in Own Shares
18th Mar 202610:10 amRNSAnnual Financial Report and Notice of AGM
16th Mar 20269:29 amRNSTransaction in Own Shares
16th Mar 20269:29 amRNSTransaction in Own Shares
11th Mar 202610:09 amRNSDirector/PDMR Shareholding
11th Mar 202610:09 amRNSDirector/PDMR Shareholding
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20264:56 pmRNSTotal Voting Rights
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:05 amRNSLaunch of Buyback Programme
26th Feb 20267:00 amRNSFinal Results, Share Buyback & Leadership Changes
4th Feb 20265:29 pmRNSStatement regarding Hikma Pharmaceuticals Plc
3rd Feb 20267:00 amRNSNotice of Results
19th Dec 20253:50 pmRNSDirector/PDMR Shareholding
19th Dec 20253:50 pmRNSDirector/PDMR Shareholding
19th Dec 20253:43 pmRNSDirector/PDMR Shareholding
19th Dec 20253:43 pmRNSDirector/PDMR Shareholding
15th Dec 20253:59 pmRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSHikma announces CEO change and Board appointment
11th Nov 202512:13 pmRNSHolding(s) in Company
11th Nov 202511:42 amRNSDirector/PDMR Shareholding
7th Nov 202512:56 pmRNSDirector/PDMR Shareholding
6th Nov 20257:00 amRNSNovember Trading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.